Novel insights for high mobility group box 1 protein-mediated cellular immune response in sepsis:A systemic review
10.5847/wjem.j.issn.1920-8642.2012.03.001
- Author:
Li-Feng HUANG
1
;
Yong-Ming YAO
;
Zhi-Yong SHENG
Author Information
1. Department of Microbiology and Immunology
- Publication Type:Journal Article
- Keywords:
High mobility group box 1 protein;
Sepsis;
Immunological effect;
Cytokine;
Signal transduction
- From:
World Journal of Emergency Medicine
2012;3(3):165-171
- CountryChina
- Language:English
-
Abstract:
BACKGROUND: High mobility group box 1 protein (HMGB1) is a highly conserved, ubiquitous protein in the nuclei and cytoplasm of nearly all cell types. HMGB1 is secreted into the extracellular milieu and acts as a proinflammatory cytokine. In this article we reviewed briefly the cellular immune response mediated by HMGB1 in inflammation and sepsis. METHODS: This systemic review is mainly based on our own work and other related reports. RESULTS: HMGB1 can actively affect the immune functions of many types of cells including T lymphocytes, regulatory T cells (Tregs), dendritic cells (DCs), macrophages, and natural killer cells (NK cells). Various cellular responses can be mediated by HMGB1 which binds to cell-surface receptors [e.g., the receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR)2, and TLR4]. Anti-HMGB1 treatment, such as anti-HMGB1 polyclonal or monoclonal antibodies, inhibitors (e.g., ethyl pyruvate) and antagonists (e.g., A box), can protect against sepsis lethality and give a wider window for the treatment opportunity. CONCLUSION: HMGB1 is an attractive target for the development of new therapeutic strategies in the treatment of patients with septic complications.
